Sign in Subscribe
Cancer research

Improved Survival Rates for Colon Cancer Patients with Deficient Mismatch Repair and/or Microsatellite Instability

Strategic Insights

— 1 min read

Researchers have made significant findings in the field of oncology, revealing improved survival rates for patients with deficient mismatch repair and/or microsatellite instability-high metastatic colorectal cancer. A multi-center study conducted by investigators at the IRCCS Foundation National Cancer Institute, in collaboration with AstraZeneca, demonstrated the efficacy of dual PD-1/CTLA-4 blockade with nivolumab and ipilimumab in improving progression-free survival over chemotherapy and anti-PD-1 monotherapy. The study involved 711 patients, with 51.2% receiving chemotherapy with or without biologics, 37.1% anti-PD-1 monotherapy, and 11.7% dual checkpoint blockade.

Key Takeaways:

  • The study showed that patients with deficient mismatch repair and/or microsatellite instability-high metastatic colorectal cancer were highly sensitive to immune checkpoint inhibitors (ICIs), with dual PD-1/CTLA-4 blockade demonstrating superior progression-free survival over chemotherapy and anti-PD-1 monotherapy.
  • The research involved 711 patients, with 51.2% receiving chemotherapy with or without biologics, 37.1% anti-PD-1 monotherapy, and 11.7% dual checkpoint blockade.
  • The study found that the prognostic impact of several clinical features did not seem to be retained in patients treated upfront with ICIs combination.
  • The investigators noted that the results of this study were particularly significant, as they demonstrated the efficacy of ICIs in improving survival rates for patients with metastatic colorectal cancer.

Statistics:

  • 51.2% of patients received chemotherapy with or without biologics.
  • 37.1% of patients received anti-PD-1 monotherapy.
  • 11.7% of patients received dual checkpoint blockade.
  • 711 patients were involved in the study.
  • The study demonstrated a significant improvement in progression-free survival with dual PD-1/CTLA-4 blockade (HR: 0.14; P < 0.0001).
  • The research found that the prognostic impact of several clinical features did not seem to be retained in patients treated upfront with ICIs combination.

Sources:

  • NewsRx. Researchers' Work from IRCCS Foundation National Cancer Institute Focuses on Colon Cancer (First-line Pd-1+/- Ctla-4 Blockade In Patients With Deficient Mismatch Repair And/or Microsatellite Instability-high Metastatic Colorectal Cancer). Cancer Weekly. October 28, 2025; p 1503.
  • The Oncologist. First-line Pd-1+/- Ctla-4 Blockade In Patients With Deficient Mismatch Repair And/or Microsatellite Instability-high Metastatic Colorectal Cancer. 2025;30(9).

Read more